Avioq® HTLV-I/II Microelisa System
The Avioq HTLV-I/II Microelisa System is intended as a screen for donated blood and organs to prevent transmission of HTLV-I and HTLV-II to recipients of cellular blood components and as an aid in clinical diagnosis of HTLV-I or HTLV-II infection and related diseases.
Derived from purified and inactivated HTLV-I viral lysate, a purified HTLV-II viral lysate, and a recombinant HTLV-I p21E antigen, the Avioq HTLV-I/II Microelisa System is an enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of antibodies to HTLV-I/II in human serum or plasma.
Confidence in Results
Excellent performance characteristics to provide the “Right Answer Sooner”
99.95% specificity in random donor population seen in clinical trials
100% Sensitivity as seen in clinical trials
(95% confidence interval of 99.97 to 100%)
99.95% specificity in random donor population seen in clinical trials
100% Sensitivity as seen in clinical trials
(95% confidence interval of 99.97 to 100%)
Ease of Use
Fast, convenient procedure with no sample
pre-dilution step
Direct dilution into microplate well
pre-dilution step
Direct dilution into microplate well
Time & Cost Savings
Excellent sensitivity and specificity in clinical trials providing reduced cost for confirmatory testing
High correlation between initial and repeat
duplicate results
High correlation between initial and repeat
duplicate results
Technology
Kit Configuration
Test Principle
Literature
Technology
Derived from purified and inactivated HTLV-I viral lysate, a purified HTLV-II viral lysate, and a recombinant HTLV-I p21E antigen, the Avioq HTLV-I/II Microelisa System is an enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of antibodies to HTLV-I/II in human serum or plasma.
The Avioq HTLV-I/II Microelisa System is intended as a screen for donated blood and organs to prevent transmission of HTLV-I and HTLV-II to recipients of cellular blood components and as an aid in clinical diagnosis of HTLV-I or HTLV-II infection and related diseases.
Developed as a standard two-step indirect microelisa system assay, the Avioq HTLV-I/II Microelisa System contains coated 96-well microwell plates, color-coded, liquid negative and positive controls.
Kit Configuration
The product is available in three kit configurations, the 192, 576, and 9600 test kits. Please refer to the ‘Literature’ tab for additional information, as well as the performance characteristics of this product. The Package Insert is available in the ‘Support’ menu tab.
Test Principle
The Avioq HTLV-I/II Microelisa System is an enzyme-linked Immunosorbent assay in which the solid phase (Microwells) is coated with a purified HTLV-I viral lysate, a purified HTLV-II viral lysate, and a recombinant HTLV-I p21E antigen.
With the addition of a diluted test sample containing antibodies to either HTLV-I or HTLV-II, complexes are formed by the interaction of the antibodies in the sample and the solid phase antigens. Following incubation, the sample is aspirated and the well is washed with buffer. Subsequently, anti-human immunoglobulin (goat) conjugated with horseradish peroxidase (HRP) is added which binds the antibody-antigen complex during a second incubation.
Following a wash and incubation with TMB (Tetramethylbenzidine) substrate, a blue color is produced. The enzyme reaction is stopped by the addition of a sulfuric acid solution which changes the color to yellow. The amount of antibody present in the sample is proportional to color development.
Literature